Company patents
MedImmune, LLC
MedImmune, LLC's patent strategy reveals a strong, albeit recently decelerating, focus on core pharma_biotech areas, with Peptides & Proteins constituting 87.3% of its portfolio. While categories like Pharmaceutical Preparations and Therapeutic Activity (Pharma) saw significant declines in 2025 (20.0% and 33.3% YoY, respectively), the dramatic drop in patent filings across almost all categories so far in 2026 (e.g., Peptides & Proteins down 95.0% YoY) suggests a significant shift in patenting activity, though 2026 data is partial.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
79 US filings (since 2023) · 10 categories · 14 themes
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Computational methods and systems for analyzing biological data (e.g., genomic, proteomic, clinical) to diagnose diseases, predict patient prognosis, assess treatment response, or stratify patients for therapy.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Patents
Showing 1-9 of 9
Cellular Immunotherapy